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Abstract 
Objective: Cutaneous squamous cell carcinoma (SCC) is the second most frequent 
skin tumor with 60 to 100-fold higher incidence in immunocompromised patients 
particularly organ transplant recipients (OTR). Chromosomal instability on 9p21-22 
encompassing the tumor suppressor gene p16 is a frequent hallmark of 
carcinogenesis in a variety of tumors. To date there is no data comparing 
chromosomal instability at 9p21-22 with p16 protein expression in SCC and no data 
in OTR.  
Design: In a select population of intraepitelial and subsequent invasive SCC from the 
same anatomical region of the same patient at different time points we assessed loss 
of heterozygosity (LOH) at 3 microsatellites IFNA, D9S162 and D9S925 in the course 
of carcinogenesis in OTRs and immunocompetent patients.  
Settings: Department of Dermatology. University Hospital Zurich 
Patients: Immunocompetent patients and OTR with SCC on sun damaged skin 
Main outcome measure: Chromosomal allelic balance in SCC of OTR and 
immunocompetent patients 
Results: Reduced allelic balance at IFNA, D9S162 and D9S925 in intraepithelial 
forms of SCC and similar allelic imbalance in invasive forms has been found. Allelic 
balance at D9S162 was reduced for SCC in OTR compared to SCC in 
immunocompetent patients. The study revealed broadly reduced allelic balance at 
9p21-22 in all cutaneous SCC while OTR presented a further reduced allelic balance 
for D9S162, suggesting a common trait for SCC in OTR. AK and BD differed in allelic 
balance at D9S162, suggesting substantial differences in their carcinogenesis. 
Conclusions:  Reduced allelic balance around locus D9S162 is a genomic correlate 
for enhanced carcinogenesis in OTRs. 
 
 
Introduction 
 
Squamous cell carcinoma of the skin (SCC) is a common cutaneous neoplasm of 
keratinocytes mainly in Caucasians. In the setting of chronic immunosuppression 
such as in organ transplant recipients (OTR), SCC incidence rises dramatically 65- to 
a 100-fold compared to the general population 1 . Chronic UV damage is a major risk 
factor and results in keratinocyte DNA damage, both initiating and propagating SCC 
formation. Intraepithelial lesions such as actinic keratosis (AK) and Bowen’s disease 
(BD) are increasingly considered in situ SCC 2, 3.  
 
The occurrence of SCC is not an isolated event, but it indicates field cancerization, 
i.e. the presence of wide-spread DNA damage in keratinocytes of sun-exposed skin 
which keeps giving rise to intraepithelial and invasive SCC in affected patients 4. 
Genomic instability is a hallmark of many different neoplasias. The resultant allelic 
imbalance or loss of heterozygosity (LOH) at particular loci can be used as marker 
for an ongoing neoplastic process. Mutations on chromosome 9p have been 
described in a variety of tumors 5-9. In SCC, LOH encompassing 9p21-22 occurred in 
41% 10. Rehman and co-workers found 20% of AK with LOH of eight or more alleles, 
39% of which on chromosome 9p 11. 
 
Cyclin-dependent kinase inhibitor p16INK4 specifically inhibits progression through G1 
phase of the cell cycle by blocking the cyclin-dependent kinase 4 from 
phosphorylating the retinoblastoma protein 12. LOH as well as loss of parts or the 
entire short arm of chromosome 9, where p16INK4 maps to 9p21, are frequently 
observed in SCCs 13, 14. Nilsson et al. 15 found weak and cytoplasmatic p16INK4a 
expression in AK, strong nuclear and cytoplasmatic p16INKa expression in carcinomas 
 
 
in situ (BD) and variable p16INK4a expression in invasive SCC. Blokx and colleagues 
assessed p16 and p53 protein expression in 23 AK (termed low-grade KIN), 28 BD 
(high-grade KIN) and 35 invasive SCCs from 44 OTR and 42 immunocompetent 
patients (ICP) concluding that p16 expression was independent of immune status 
and of p53 expression 16. Other tumor suppressor genes located in the 9p21-22 
region include INK4b and ARF (Alternative Reading Frame) 17-19. 
 
The aim of the study was to recognize the imprint of field cancerization in the course 
of carcinogenesis in a highly select population of first intraepitelial and subsequently 
invasive SCC from the same anatomical region of the same patient at different time 
points. Allelic imbalance on 9p21-22 as a well-known highly variable region in SCC 
has been analyzed. Because OTR empirically show a greatly increased SCC 
incidence and are known to harbor genetic damage in addition to the one generally 
incurred by UV damage alone 20, 21, SCC of both ICP and OTR were included.  
 
 
 
Material and Methods 
Ethical considerations 
The use of clinically indicated biopsy material for the study was approved by the 
ethical committee of the Canton of Zurich, Switzerland.  
 
Patients and tumor selection 
The goal was to obtain tissue material from an area of field cancerization which had 
first given rise to an intraepithelial and at least one year later to an invasive 
squamous cell carcinoma of the skin. Following approval by the local ethical 
committee, paraffin-embedded archival tissue specimens from 43 immunocompetent 
patients and 42 immunosuppressed organ transplant recipients were randomly 
included, all of which first had an intraepithelial form of cutaneous squamous cell 
carcinoma such as actinic keratosis or Bowen’s disease, followed by an invasive 
squamous cell carcinoma of the skin in the same anatomical region at least one year 
later. These intraepithelial forms were then intraindividually compared to the 
subsequent invasive squamous cell carcinoma. Of the 42 organ transplant recipients, 
32 were kidney, 4 lung, and 6 heart recipients (table 1). All tumors were located on 
chronically sun-exposed skin of the head, neck and upper extremities.  The 
histological diagnosis was made by a board-certified dermatopathologist based on 
the criteria defined by the WHO classification of skin tumours 22. Actinic keratoses 
and Bowen’s disease were on the one hand analysed separately and compared to 
each other, and on the other hand and grouped as “intraepithelial SCC” the cases of 
actinic keratosis and Bowen’s disease to compare them to invasive SCC. 
 
Microdissection 
 
 
From each sample 3-5 adjacent sections of 10 µm thickness were stained with 
hematoxylin and eosin. Microdissection was performed under a light microscope 
(magnification 400X).  In each sample, 150 tumor cells were selectively removed 
using a disposable 30 gauge needle. In addition, 150 normal skin cells (apocrine 
glands and endothelial cells in far distance from the tumor) were harvested from the 
same slides and served as internal controls.  
 
DNA extraction 
Microdissected cells were immediately suspended in 20 µl digestion solution 
containing 50 mM Tris-HCl, 1 mM EDTA, 1% Tween 20 and 2.5 mg/ml proteinase K 
(pH 8.0,  Sigma-Aldrich, P2308,  Inc., Saint Louis, MO, USA) and incubated for 16 
hours at 37°C. The mixture was then heated for 10 min at 94°C to inactivate 
proteinase K.  5 µl of this solution was used as the template DNA for polymerase 
chain reaction (PCR) amplification. 
 
Primers and PCR conditions 
To establish a highly reproducible LOH-analysis for cutaneous squamous cell 
carcinoma, 3 microsatellite marker loci on chromosome 9 (IFNA, D9S925, D9S162) 
previously linked to early tumor development 23 and flanking the p16 tumor 
suppressor gene region have been selected. These loci included either di- or tetra-
nucleotide tandem repeats known for their high degree of allelic variability and hence, 
informativity (table 2). PCR of the 3 different microsatellite markers was performed 
with separate primer pairs of which 1 oligonucleotide was labeled at the 5’-end with 
the fluorescent dyes 6-FAM, HEX (Microsynth, Balgach, Switzerland) or NED 
(Applied Biosystems, Rotkreuz, Switzerland).  The primer sequences were as 
follows:  IFNA up: GTAAGGTGGAAACCCCC (FAM), IFNA low: 
 
 
TGCGCGTTAAGTTAATTGG, D9S162 up: CCAGAGAAACAGAACCA (NED), 
D9S162 low: ACAACAAATCTCCTCACA, D9S925 up: 
TGTGAGCCAAGGCCTTATAG (HEX), D9S925 low: GTCTGGGTTCTCCAAAGAAA. 
Amplification of specific DNA was done in a reaction volume of 25 µl including 0.2 
mM dNTPs (Roche Diagnostics), 2.5 mM MgCl2, 0.5 U AmpliTaq Gold (both from 
Applied Biosystems). Cycling was performed with a GeneAmp PCR System 9700 
(Applied Biosystems) using the following temperature conditions: 94°C for 1 min, 
55°C for 1 min, 72°C for 2 min for 40 cycles; final extension 60 min at 60°C. The PCR 
products were subsequently denatured for 1 min at 95°C in HiDi formamide (Applied 
Biosystems) and separated on an ABI PRISM 3100 Genetic Analyzer equipped with 
a 36 cm capillary array loaded with POP-4 polymer. ROX-400HD was used as 
internal size standard (Applied Biosystems). Generally artefacts can be a concern in 
LOH analysis. PCR for each locus has been performed twice with similar results. 
Moreover a large number of samples was analyzed which allows for statistical 
assurance of true allelic imbalance. 
 
Loss of heterozygosity (LOH) analysis 
Analysis of the samples was carried out with the GeneMapper software version 3.7 
(Applied Biosystems). A case was considered informative for a polymorphic marker if 
normal tissue DNA showed two different alleles.  To identify samples with LOH, the 
allelic balance ratios of heterozygous markers from the cutaneous SCC DNA and 
from the patient’s control DNA (from normal skin cells) were compared. Briefly, the 
ratio of the peak areas of the 2 alleles amplified from the tumor sample was divided 
by the peak areas of the 2 alleles from the control DNA. When the result of this 
calculation surmounted 1, the reciprocal value was used instead. Consequently, the 
calculated numbers varied between 0 (representing complete loss) and 1 (retained 
 
 
heterozygosity). To determine if allelic imbalance ratio in a tumor sample met the 
criterion for LOH, previously published standard threshold values for these three loci 
were applied 24. 
 
Immunohistochemistry 
3- to 5-μm adjacent sections were used for hematoxylin and eosin (HE) staining and 
immunohistochemistry. The deparaffinized sections were heated in a 100-W 
household microwave oven at maximum power for three times 5 minutes each in 10 
mmol/L citric acid for antigen retrieval. Primary antibody was then applied for 60 
minutes at room temperature. Immunohistochemical stainings were performed with 
monoclonal IgG mouse antibodies specifically binding human p16INK4a (G175-405; 
550834, PharMingen, San Diego, CA, 1:200) and p53 (DO-7, Pab 1801, Sigma 
Biosciences, St Louis, MO, USA, 1:100).  Secondary staining was performed using 
the alkaline phosphatase anti-alkaline phosphatase method 25. Normal epidermis and 
dermal cells served as internal negative controls. Sections of benign melanocytic 
nevi and breast cancer tissue served as external positive controls. Immunoreactivity 
was rated as 0-5%, 6-25%, 25-50%, 51-75%, 76-100% positive tumor cells. All 
samples were reviewed unaware of the patients’ diagnosis or immune status.  
 
Statistical analysis 
Allelic balance ratios and immunoreactivity between two independent groups were 
calculated using the Mann Whitney U Test, frequencies of LOH between two groups 
using Fisher’s Exact Test.. Correlations between LOH, p16 and p53 were expressed 
using Spearman’s rho.  P-values <0.05 were considered statistically significant. 
Statistical analyses were performed using SPSS for Windows 11.5 (SPSS Inc., 
Chicago, IL, USA), GraphPad Prism 5.0 and Microsoft Excel 2000.   
 
 
 
 
Results 
 
Considerably reduced allelic balance on microsatellite loci IFNA, D9S162 and 
D9S925 on chromosome 9p is similar in intraepithelial and invasive SCC. 
Considerable allelic imbalance at all three microsatellite loci has been found. Median 
allelic balance in all tumors was 0.80 for IFNA (n=73), 0.76 for D9S162 (n=86) and 
0.75 for D9S925 (n=95) (mean 0.73, 0.69 and 0.71, respectively). At all three loci, 
there was no reduction in allelic balancethere was no increase in allelic imbalance on 
the course from intraepithelial to invasive SCC (IFNA 0.79 for intraepithelial SCC, 
0.80 for invasive SCC, n=20, p=0.56; D9S162 0.72, 0.77, n=29, p=0.47; D9S925 
0.80, 0.73, n=31, p=0.58, Wilcoxon matched pair test, two-tailed p-values) (Figure 
1(a)) Loss of heterozygosity (LOH) defined as allelic balance below threshold values 
for these three loci (supplementary table 1) was found in 61.6% of informative 
samples at locus IFNA, in 41.9% at D9S162 and in 50.5% at D9S925. LOH was 
frequent already in intraepithelial SCC (IFNA 60.0%, D9S162 39.5%, D9S925 40.0%) 
and did not increase significantly on the course to invasive SCC (63.6%, 44.2%, 
60.0%, respectively; data not shown).  
 
Allelic balance at D9S162 is reduced for SCC in OTR compared to SCC in 
immunocompetent patients. 
The analysis detected reduced allelic balance at D9S162 in OTR compared to ICP 
(0.70 vs. 0.76; p=0.04, n=37, n=49, respectively) (Figure 1(b)). Allelic balance at 
IFNA and D9S925 was similar between ICP and OTR. LOH as defined by threshold 
values (supplementary table 1) was more frequent at D9S162 in OTR than in ICP 
(34.8% vs. 45.0% of informative samples, p=0.04, but similar at IFNA and D9S925 
(data not shown).  
 
 
 
Actinic keratosis shows reduced allelic balance at D9S162 compared to Bowen’s 
disease. 
Allelic balance for all samples of actinic keratosis together is reduced at D9S162 
(0.69) in contrast to Bowen’s disease (0.84; p=0.004). At IFNA and D9S925 AK and 
BD show similar allelic balance (0.83, 0.75 and 084, 0.79, respectively) (Figure 2(a)). 
LOH as defined by the respective threshold values is significantly less frequent in BD 
at D9S162 than in AK (50% vs. 10%, p=0.03) (data not shown).  
 
The difference in allelic balance for D9S162 between AK and BD is primarily found in 
OTR neoplasms 
Subgroup analysis in OTR reveals that the allelic difference observed for AK and BD 
overall stems mainly from neoplasms in OTR: the allelic balance at D9S162 is higher 
in BD than in AK (0.93, n=10, 0.61, n=13, respectively; p=0.01) (Figure 2(b)). In the 
ICP subgroup there is no significant difference between AK and BD at D9S162 
(p=0.09, data not shown). Intraepithelial SCC overall did not differ between OTR and 
ICP in allelic balance at any of the three loci (data not shown). 
 
Pronounced p16 expression in Bowen’s disease (BD) compared to actinic keratosis 
(AK) is primarily found in OTR, not ICP.  
p16 immunoreactive tumor cells were found in a higher proportion in BD (n=22 
samples) than in AK (n=63) (p=0.0001 for all BD versus AK). This was primarily due 
to the expression difference in OTR intraepithelial SCC (BD n=13, AK n=29, 
p=0.0002), while p16 expression did not differ between BD and AK in ICP (p=0.70) 
(figure 2(c)). 
 
 
 
Invasive SCC in OTR shows reduced allelic balance for D9S162 compared to 
invasive SCC in immunocompetent patients  
The difference in allelic balance found for all SCC between OTR and ICP is primarily 
due to the invasive SCC subgroup: In invasive SCC, allelic balance at D9S162 was 
reduced in OTR (0.62) compared to ICP (0.82, p=0.04, n=17, n=26, respectively) 
(Figure 3(a)).  
 
Higher proportion of p16 immunoreactive tumor cells in invasive SCC in OTR than in 
ICP. 
In all SCC together, p16 protein expression was upregulated compared to normal 
skin and similar between ICP and OTR (p=0.23; data not shown). Subgroup analysis 
of invasive SCC, however, revealed higher proportions of p16 immunoreactive tumor 
cells in OTR than in ICP (p=0.0001, Figure 3(b)).  
 
p16 and p53 protein expression do not correlate with allelic balance at IFNA, D9S162 
and D9S925. 
As the gene locus for p16 is flanked by microsatellite loci IFNA and D9S162, the 
correlation between p16 immunoreactivity and allelic imbalance at the three 
microsatellite markers has been assessed. p16 protein expression did not correlate 
with allelic balance at the three loci (IFNA rho=0.09, D9S162 rho=0.056, D9S925 
rho=0.131) (table 2). p53 expression, which was determined as a tumor suppressor 
protein not coded on 9p21-22 and frequently upregulated in SCC, was found 
upregulated in all SCC to a similar degree without differences (data not shown). P53 
protein expression also did not correlate with allelic balance at the three loci (IFNA 
rho=-0.001, D9S162 rho=0.105, D9S925 rho=-0.132) (table 2). We previously also 
 
 
analysed HPV protein expression by immunohistochemistry in these samples and 
found it to be very low 26. 
 
 
Discussion 
A highly selected SCC sample group has been analysed: the samples were all paired 
from the same patient and the same anatomical region with first an intraepithelial and 
at least a year later an invasive SCC which were available for study. Such careful 
selection allows closer observation of allelic imbalance in the course of SCC 
development, in particular in the transition of SCC across the dermo-epidermal 
junction and may yield meaningful insight with a limited number of samples 26, 27.  
 
The analysed region of the chromosome 9p21-22 is a well-known highly variable 
region in SCC of different organs. One of the genes located in this region is cyclin-
dependent kinase inhibitor p16INK4 . The P16 protein is known to specifically inhibit 
progression through the G1 phase of the cell cycle by blocking the cyclin-dependent 
kinase 4 from phosphorylating the retinoblastoma protein. Thus this gene may play 
the role of an antioncogene. We aimed to study the allelic imbalance and putative 
consequence in p16 protein expression levels. Our study shows a difference in both 
allelic imbalance at 9p21-22 and p16INK4 expression between the AK and BD, which 
suggests a role of this particular chromosomal locus for SCC carcinogenesis. 
The chromosomal region 9p21-22 in our SCC samples is broadly impaired in its 
allelic balance, a common finding for all samples assessed. These findings are in line 
with previously published data on SCC and other neoplasms 5-11. Rehman and co-
workers found, that 20% of AK showed LOH of eight or more alleles, 39% of which 
from 9p 11. In a study on LOH in SCC, Quinn and colleagues found LOH in a distinct 
region encompassing 9p21-22 to occur in 41% 10. This led to the hypothesis that the 
tumor-suppressor gene CDKN2A may play a critical role in SCC development. 
Mutational analysis and loss of transcript expression further suggests that 
inactivation of CDKN2A is important for SCC progression 28-31. In contrast to basal 
 
 
cell carcinoma, the pattern and degree of LOH in SCC were more diverse and 
widespread. This suggests that increase allelic imbalance on 9p21-22 in early lesions 
such as AK and BD supports the notion that AK, BD and invasive SCC are part of the 
same continuum of SCC 2, 32 and that DNA damage at 9p21-22 may be an early 
event in the carcinogenesis of SCC. 
 
The marker D9S162 in particular showed a loss of allelic balance that distinguished 
SCC in OTR from SCC in immunocompetent patients and was most varied in all 
comparisons made. Not only did SCC in OTR show a reduced allelic balance for this 
marker, but allelic balance of D9S162 distinguished AK from BD for all intraepithelial 
lesions with OTR contributing primarily to this difference. Invasive SCC again showed 
allelic balance of D9S162 reduced in OTR compared to immunocompetent patients. 
Increased and particular patterns of DNA damage have been reported in OTR and 
ascribed to e.g. the effect of azathioprine 1, 21 Azathioprine is an antimetabolite which 
doubles photosensitivity to UVA in keratinocytes and enables direct DNA damage by 
UVA 20. While the underlying factors cannot be differentiated in the studied samples, 
these results may suggest  that pronounced loss of allelic balance for D9S162 seems 
particular to SCC in OTR compared to SCC in the general, immunocompetent 
population.  
 
Actinic keratosis was initially grouped with Bowen's disease as intraepithelial SCC for 
our analysis. Allelic balance on 9p21-22, however, differed greatly for these two 
conditions, yielding a clear reduction of allelic balance for AK compared to BD. This 
suggests that BD may be set apart in its early mutational steps from the continuum of 
AK and invasive SCC. The gene locus for p16 is flanked by microsatellite loci IFNA 
and D9S162, thus allelic imbalance in these markers may affect expression of this 
 
 
tumor suppressor protein. Indeed, AK showed a lower expression of p16 by 
immunohistochemistry. As for allelic imbalance, the expression difference for p16 
was mainly found within intraepithelial lesions of OTR. Two immunohistochemical 
studies, evaluating p16INK4 expression in AK, Bowen’s disease and SCC of the skin 
presented rather controversial results. Hodges and co-workers 33 found 
immunoreactivity in about all AK and Bowen’s disease but only in 30% of invasive 
SCC whereas Salama and colleagues 34 showed a high frequency of 
immunoreactivity for BD but very little for AK and none for SCC. From this they 
concluded that p16INK4 is a selective and specific marker to distinguish BD from SCC. 
This study shows that AK in OTR is set apart from BD by reduced allelic balance on 
9p21-22 and reduced p16 expression, suggesting different paths of carcinogenesis 
for AK and BD in OTR.  
 
Drug-induced immunosuppression in OTR dramatically increases SCC 60- to 100-
fold 35. Immunosuppressants also act directly on keratinocytes 1, some on the 
transcriptional level such as cyclosporine A on ATF3 36 and some on the genomic 
level such as azathioprine in conjunction with UVA 20. Blokx and colleagues 
assessed p16 and p53 protein expression in 23 AK (named it low-grade KIN), 28 BD 
(high-grade KIN) and 35 invasive SCCs from 44 OTRs and 42 immunocompetent 
controls and came to the conclusion, that p16 expression was independent of 
immune status and also independent of p53 expression 16. This study shows that 
invasive SCC in OTR exhibits reduced allelic balance for D9S162, but in contrast to 
intraepithelial SCC, p16 expression seems increased in SCC of OTR compared to 
SCC of the general population.  
 
 
 
Nilsson et al. 15 found weak and cytoplasmatic p16INK4a expression in AK, strong 
nuclear and cytoplasmatic p16INKa expression in carcinomas in situ (BD) and variable 
p16INK4a expression in invasive SCC. While the allelic balance in OTR seems 
reduced for all samples at 9p21-22, in particular for OTR, the upregulation of p16 
expression in SCC of OTR is at this time difficult to interpret and suggests that in 
OTR not a lack of p16 protein expression but other mechanisms are involved in 
enhanced cutaneous squamous cell carcinogenesis. The presented data on the low 
correlation of allelic balance at 9p21-22 and tumor-suppressor protein p16 and p53 
expression underlines this difficulty. We conclude that SCC of OTR, both 
intraepithelial and invasive, show a reduced allelic balance on 9p21-22 compared to 
the general population’s SCC as a common trait. The expression of p16 seems not 
affected by such allelic imbalance at 9p21-22.  
 
In summary, allelic balance at 9p21-22 broadly reduced in all SCC has been found, 
while OTR presented even further reduced allelic balance for D9S162, suggesting a 
common trait for SCC in OTR. AK and BD differ in allelic balance at D9S162, in 
particular among OTR, suggesting essential differences in their carcinogenesis. 
Tumor suppressor protein p16, while located close to the observed reduced allelic 
balance, shows no close relationship to the allelic balance observed, nor does p53.  
The allelic imbalances found in our study suggest a role for them in the increased 
and more aggressive carcinogenesis in OTR. Our results add to the rationale of a 
tight clinical follow-up for OTR to recognize and treat intraepithelial SCC early, 
preferably addressing field cancerization. 
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Figure legends 
 
Figure 1. (a) Allelic balance is similarly reduced in all SCC (intraepitelial and 
invasive). Allelic balance ratios in intraepithelial (black box plots) and invasive SCC 
(white box plots). Whiskers of box plots represent 9- and 95-percentiles. Two-tailed 
p-value from Wilcoxon matched pairs test.  n.s.: non-significant.  Total number of 
patients n=85. IFNA informative paired samples: n=20, p=0.56, D9S162 informative 
paired samples: n=29, p=0.47, D9S925 informative paired samples: n=31, p=0.58. 
(b) SCC in OTR overall show reduced allelic balance for D9S162 compared to 
SCC in immunocompetent patients. Allelic balance ratios in SCC in 
immunocompetent (ICP, black box plots) and immunosuppressed (OTR, organ 
transplant recipients, white box plots) patients. Whiskers of box plots represent 9- 
and 95-percentiles. Two-tailed p-value from Mann Whitney U test.  n.s.: non-
significant. Total number of SCC n=170. IFNA informative samples: 
Immunocompetent=42, OTR=31, D9S162 informative samples 
immunocompetent=49, OTR=37, D9S925 informative samples: 
immunocompetent=49, OTR=46. Two-tailed p-value from Wilcoxon matched pairs 
test. n.s.: non-significant. 
 
Figure 2. (a) Overall, AK show reduced allelic balance for D9S162 compared to 
BD. Allelic balance ratios in actinic keratosis (AK, black box plots) and Bowen’s 
disease (BD, white box plots). Bowen‘s disease shows significantly higher allelic 
balance at D9S162 than actinic keratosis (p=0.0038). IFNA informative samples: 
AK=30, BD= 10, D9S162 informative samples AK=32, BD=11, D9S925 informative 
samples: AK=31, BD=14. Two-tailed p-value from Mann Whitney U test. Total 
number of AK=63, Bowen‘s disease=22. (b) AK in OTR show less allelic balance 
 
 
for D9S162 than BD in OTR. (p=0.01, Mann Whitney U test). Allelic balance ratios in 
actinic keratosis (AK, black box plots) and Bowen’s disease (BD, white box plots) in 
OTR. IFNA informative samples: AK=12, BD= 5, D9S162 informative samples: 
AK=13, BD=7, D9S925 informative samples: AK=13, BD=10. Total number of 
intraepithelial SCC in OTR: AK=29, Bowen‘s disease=13. Fisher’s exact test. (c) AK 
in OTR express less p16 protein than BD in OTR (p<0.005, ANOVA). Y-axis: SCC 
samples in absolute numbers. X-axis: Proportion of p16 immunoreactive tumor cells 
grouped by percent of immunoreactive cells within tumor.  
 
Figure 3. (a) Invasive SCC in OTR shows reduced allelic balance for D9S162 
compared to invasive SCC in immunocompetent patients (p=0.048, two-tailed p-
value from Mann Whitney U test). Allelic balance ratios in invasive SCC in 
immunocompetent patients (ICP, black box plots) and organ transplant recipients 
(OTR, white box plots). IFNA informative samples: Immunocompetent=19, OTR=14, 
D9S162 informative samples immunocompetent=26, OTR=17, D9S925 informative 
samples: immunocompetent=27, OTR=23. Total number of invasive SCC n=85. (b) 
Invasive SCC of OTR express more p16 protein than invasive SCC of 
immunocompetent patients (p=0.001, ANOVA). Organ transplant recipients (OTR) 
compared to immunocompetent patients (ICP). Y-axis: absolute number of SCC 
samples. X-axis: Proportions of p16 immunoreactive tumor cells in intraepithelial and 
invasive SCC in ICP and OTR grouped by percent of immunoreactive cells within 
tumor.  
 
 
 
Table legends 
 
Table 1 
Patient characteristics. Immunocompetent: Immunocompetent patients. OTR: organ 
transplant recipients. Transplanted organs were: 32 kidney, 6 heart, 4 lung. 
 
Table 2 
Correlation (Spearman’s rho) between allelic balance ratio for IFNA, D9S162 and 
D9S925, p16 and p53 protein expression and corresponding p-value.  
 
 
Table 1 
Patient characteristics 
  Immunocompetent OTR Total 
Patients 43 42* 85 
Gender:  
male [n (%)] 
 
32 (74) 
 
36 (86) 
 
68 (80) 
Age [mean (± SD)] 66.0 (±0.74) 61.3 (±1.07) 63.7 (±0.67) 
Age [Min / Max] 47.6 / 81.5 36.1 / 79.5 36.1 / 81.5 
Diagnoses    [n (%)]    
- Actinic keratosis 34 (40) 29 (34) 63 (37) 
- Bowen’s disease 9 (11) 13 (16) 22 (13) 
- Squamous cell carcinoma 43 (50) 42 (50) 85 (50) 
 
*  kidney:  32,   heart:  6,   lung:  4 
 
 
 
 
 
Table 2 
 
  D9S162  D9S925  p16  p53  
 [Spearman’s rho] 
[p-value] 
IFNA .320 
.015 
.630 
.000  
.086 
.468 
-.001 
.993  
D9S162   .567 
.000 
.056 
.605 
.105 
.359 
D9S925    .131 
.207 
-.132 
.220 
p16     .158 
.044 
 
 
 
 
 
 
 
